Table 2 Incidence of diabetes in patients receiving oral anticoagulants after atrial fibrillation
Treatment | Patients, n | Median follow-up time (IQR), d | Event, n | Median time to event (IQR), d | Crude incidence per 100 Person-years | Weighteda incidence per 100 person-years |
|---|---|---|---|---|---|---|
All patients | ||||||
Warfarin | 3454 | 222 (36–704) | 195 | 126 (16–378) | 6.3 | 6.4 |
Apixaban | 3335 | 363 (106–648) | 177 | 174 (43–364) | 5.3 | 4.9 |
Dabigatran | 4210 | 363 (84–700) | 192 | 196 (26–413) | 4.5 | 4.3 |
Rivaxaban | 2689 | 392 (98–730) | 134 | 199 (36–412) | 4.6 | 5.1 |
Women | ||||||
Warfarin | 1551 | 221 (35–702) | 78 | 154 (31–412) | 5.6 | 5.8 |
Apixaban | 1699 | 372 (106–651) | 91 | 198 (46–360) | 5.3 | 5.6 |
Dabigatran | 2018 | 364 (78–683) | 84 | 222 (18–423) | 4.2 | 3.9 |
Rivaxaban | 1282 | 416 (92–730) | 67 | 186 (34–334) | 4.7 | 5.4 |
Men | ||||||
Warfarin | 1903 | 224 (38–705) | 117 | 90 (8–344) | 6.9 | 7 |
Apixaban | 1636 | 348 (106–645) | 86 | 134 (37–372) | 5.3 | 4.1 |
Dabigatran | 2192 | 358 (88–714) | 108 | 192 (46–390) | 4.8 | 4.7 |
Rivaxaban | 1407 | 378 (102–730) | 67 | 276 (45–480) | 4.5 | 4.7 |